New Pharma Services Division Secures $1.2M Follow-On Contract for Innovative Cancer Patient Trial Assessment Approach |Andrew Newland, CEO, Angle PLC. 00:10:00
Angle PLC's new pharma services division secures a significant $1.2 million follow-on contract with a major client for its innovative approach in assessing drug trial results in cancer patients using the Parsortix system, highlighting a paradigm shift in the industry's methods and customer engagement.